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Abstract Dendritic cell (DC)-based immunotherapy is an
attractive approach to induce long lasting antitumor effector
cells aiming to control cancer progression. DC targeting is a
critical step in the design of DC vaccines in order to
optimize delivery and processing of the antigen, and several
receptors have been characterized for this purpose. In this
study, we employed the FcγRs to target DCs both in vitro
and in vivo. We designed a recombinant molecule (HER2-
Fc) composed of the immunogenic sequence of the human
tumor-associated antigen HER2 (aa 364–391) and the Fc
domain of a human IgG1. In a mouse model, HER2-Fc
cDNA vaccination activated significant T cell-mediated
immune responses towards HER2 peptide epitopes as
detected by IFN-γ ELIspot and induced longer tumor
latency as compared to Ctrl-Fc-vaccinated control mice.
Human in vitro studies indicated that the recombinant
HER2-Fc immunogen efficiently targeted human DCs
through the FcγRs resulting in protein cross-processing
and in the activation of autologous HER2-specific CD8
+ T
cells from breast cancer patients.
Keywords Dendritic cells.Cancer immunotherapy.
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Introduction
The design of cancer vaccines is finalized to control tumor
growth by activating long lasting antitumor immune
responses and removing the immunosuppressive networks
that are established during tumor progression. So far, the
harnessing of dendritic cells (DCs) in order to modulate
immune system activity is an experimental approach
gaining increasing therapeutic significance [1].
DCs are the most powerful antigen presenting cells
(APCs) and key regulators for the coordination and balance
of the innate and acquired immunity leading to T cell
activation and finally to tumor cell killing. A heterogeneous
array of receptors is employed by DCs to sense danger
signals, triggering DC maturation, and licensing [2]. The
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efficacious strategy to deliver antigen to DCs both in vivo
and ex vivo [3]. The family of Fc receptors for IgGs
(FcγRs) is an example of such molecules [4]. In vivo
uptake of IgG-soluble antigen complexes through FcγRs
leads to DC activation, secretion of pro-inflammatory
cytokines, and steers antigen processing towards MHCI
and MHCII pathways, inducing CD4
+ and CD8
+ antigen-
specific T cell responses [5].
DC targeting through activatory FcγRs has been proposed
as optimal strategy to induce efficacious antitumor immune
responses [3, 6]. DCs pulsed with immunocomplexed antigen
have shown to be superior to soluble antigen-pulsed DCs as
antitumor vaccine [7]. Moreover, in vivo studies demonstrate
that the combined administration of antitumor antibody and
tumor vaccine enhanced antitumor CD8
+ T cell response by
FcγRs-mediated activation of DCs [8]. Vaccination with
plasmids coding for immunogenic sequences fused to the Fc
fragment of human IgG1 (hIgG1 Fc) is also a strategy to target
D C si nv i v o[ 9, 10]. So far, however, the employment of
FcγR targeting in antitumor clinical setting is limited to the
treatment of hematological malignancies [11].
In this study, we designed an HER2-Fc chimera to target
DCs both in vivo and ex vivo as cancer vaccine. HER2 is a
growth factor receptor overexpressed in epithelial cancers
and is optimal target for passive and active immunotherapy
[12]. In cancer patients, natural specific immune responses
can be observed and peptide vaccination has been correlated
to a better disease outcome [13].
Results obtained in our experimental model indicate that
HER2-Fc cDNA vaccination activated HER2 specific T cell-
mediated responses and induced a significantly longer tumor
latency in mice than the control Ctrl-Fc cDNA. The
recombinant immunogen was able to target human DCs
through the FcγR, and antigen processing occurred both in
human leukocyte antigens (HLA)II and HLAI compartments.
HER2-Fc-pulsed DCs induced a significant interferon
gamma (IFN-γ) secretion by HER2 specific CD8
+ Tc e l l s
obtained from HER2
+/HLAI-A2
+ breast cancer patients.
Material and methods
Cell cultures
CHO-K1 cells were cultured in RPMI 1640 (Hyclone, UT,
USA) with penicillin 100 U/ml, streptomycin 100 μg/mL,
2 mM L-glutamine, (Sigma Company, St. Louis, MO) and
10% fetal calf serum (FCS) (Hyclone), 5% CO2 at 37°C. For
CHO-K1 transfectants, 400 μg/ml Geneticin (Invitrogen,
Germany) were added to the medium. D2F2/E2 cells,
BALB/c mammary tumor cotransfected with pRSV/neo
and human HER2 were cultured in DMEM with Glutamax1,
20% FCS, 800 μg/ml Geneticin. They were kindly provided
by Dr. Wei, Karmanos Cancer Center, Detroit.
Cloning of HER2-Fc and Ctrl-cDNA constructs
The leader sequence (LS) and HER2 cDNAs were generated
by oligonucleotide annealing. After purification, the annealed
oligonucleotides were cloned into pBS-KS
+ (Stratagene,
USA) (LS: ApaI/XhoI sites; HER2: EcoRI/PstI sites). This
sequence was used as a template to amplify HER2 cDNA
with XhoI-BamHI ends (primer A1xA2). The HER2 cDNA
was cloned at the 3′ end of the LS (cloning sites: 5′-XhoI, 3′-
BamHI) (construct pBS-KS
+LS-HER2). Fc was amplified
(B1xB2 primers) using as template the pUCγ1 and fused to
LS-HER2 (BamHI-NotI) to generate the HER2-Fc cDNA.
For the Ctrl-Fc cDNA, Fc sequence was amplified with
C1xB2 primers and cloned at the 3′ of LS in pBS-KS
+ in
XhoI-NotI sites. Both cDNAs were cloned HindIII-NotIi n t o
pcDNA3.1 Neo (Invitrogen). Large-scale preparation was
carried out with EndoFree Plasmid Giga kits (Qiagen). The
oligo sequences and experimental conditions are reported in
Supplementary Table 1.
Protein production
The CHO-K1 cells were transfected using Lipofectamine™
2000 (Invitrogen) in a 10-cm tissue culture disk following
the manufacturer’s instructions.
Transfectant supernatant was loaded onto protein A
sepharose 4B conjugate (Invitrogen). The bound protein
was eluted with 0.1 M glycine hydrochloride, pH 2.6,
neutralized (1 M Tris) and dialyzed against 0.1× PBS using
SnakeSkin® Pleated Dialysis Tubing (3.5 MWCO) (Pierce,
Rockford, USA).
Western blotting
Purified HER2-Fc and Ctrl-Fc proteins were separated on
4–12% SDS-PAGE and blotted onto nitrocellulose mem-
brane (Schleicher and Schuell, Dassel, Germany). After 5%
BSA blocking (16 h, 4°C), membranes were incubated with
anti-human IgG peroxidase-conjugated antibody (1:10,000)
(Sigma) for 1 h at room temperature and protein bands
detected by chemiluminescence (Amersham Pharmacia,
Buckinghamshire, UK).
Mice, immunization, and tumor growth
BALB/c (H-2
d) female mice were from Charles River
Laboratory and were treated according to the European
Union guidelines. The mice were anesthetized and vaccinated
as previously described [14], i.e., i.m. injections of plasmid
(50 μg) followed by electroporation. The mice were
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11 mice were used for tumor challenge experiments, while
the group of three mice were used for the analysis of immune
response. Experiments were repeated three times. For tumor
rejection studies, 1 week after the second vaccination, the
mice were challenged in the mammary pad with a lethal dose
of transfected D2F2/E2 cells with human HER2 (2×10
5).
The mammary pad was inspected weekly by palpation.
Progressively growing masses >2 mm in diameter were
regarded as tumors. The mice were sacrificed when one of
the tumors exceeded 10 mm in diameter. Differences in the
time required for the tumor to reach 2 or 10 mm in mean
diameter in each experimental group was calculated.
Mouse IFN-γ enzyme-linked immunospot assay
Splenocytes (SPCs), 1×10
6, from vaccinated mice 2 weeks
after the second vaccination were plated in triplicate on
nitrocellulose 96-well HTS IP plates (Millipore, Bedford,
MA) precoated with 5 μg/mL of rat anti-mouse IFN-γ
antibody (clone R4-6A2, BD Biosciences, Milan, Italy).
SPCs were stimulated for 16 h at 37°C with 15 μg/mL of
each peptide (Proimmune, Oxford, UK). Plates were
developed according to the manufacturer’s instruction (BD
Biosciences). Briefly, after washing with PBS 0.05% Tween
20, plates were incubated for 24 h at 4°C with 50 μl/well of
biotin-conjugated rat anti-mouse IFN-γ (BD Biosciences)
dilutedinassaybuffer.Plateswereincubatedwithstreptavidin
horseradish peroxidase conjugate (HRP, BD Biosciences).
After extensive washing, AEC substrate solution was added
until spot development. Plates were washed, and IFN-γ spots
were enumerated as previously described [15].
DC generation
DCs were generated as previously described [16]. Peripheral
blood mononuclear cells (PBMCs) were isolated from the
buffy coat of healthy donors or from blood samples of HLAI-
A2
+/HER2
+ breast cancer patients and separated by Ficoll-
Hypaque (1,077 g/mL; Pharmacia LKB, Upsala, Sweden)
gradient. Immunoselected CD14
+ monocytes were plated
(5×10
5 cells per milliliter) in CellGro® DC medium
(CellGenix, Freiburg, Germany), with rhGM-CSF (50 ng/
ml), and rhIL4 (2000 U/ml). On day 6, immature DCs (iDCs)
were matured for 16 h (mDCs) with pro-inflammatory
cytokines (R&D System). The study was approved by the
institution regulatory board and by the ethical committee.
Informed consent was obtained by cancer patients.
Fusion protein binding to DCs
iDCs (2×10
4/sample) were incubated with HER2-Fc
protein or MOPC21 (Sigma) (10 μg/ml, 2 h on ice). After
washing, DCs were incubated with fluorescein isothiocynate
(FITC)-conjugated F(ab)2 specific for anti-human Fcγ
(Jackson ImmunoResearch Laboratories, Inc., West Grove,
USA) (30 min, 4°C). To block Fcγ-R, iDCs were incubated
with anti-human FcγRIIa MoAb (StemStep) (5 μg/ml,
30 min, 4°C) before the binding procedure. Cells of 5×10
4
were evaluated using FACSCanto II flow cytometer running
CellQuest software (Becton Dickinson).
Immunofluorescence microscopy
iDCs were pulsed with HER2-Fc (10 μg/ml; 30 min on ice),
washed and incubated at 37°C (2 or 12 h). After washing, the
cellswerecytospun ontoSuperFrost® PlusMicroscopeSlides
(Menzel-Glaser, Germany) (8×10
4/sample), fixed with cold
acetone/methanol (Carlo Erba Reagents) (1:1). After the
blocking of unspecific sites, the samples were incubated for
45 min with compartment marker-specific antibodies: MoAb
anti-lysosomal-associated membrane protein 1 (LAMP1)
(E-5, Santa Cruz Biotechnology), anti-HLAI MoAb W6.32,
and rabbit polyclonal anti-calreticulin (Stressgene, Ann
Arbor, MI). Texas Red-conjugated anti-mouse (1:100) or
anti-rabbit (1:300) antibodies were used as secondary Abs
(30 min). After the blocking of aspecific sites by Superblock
(20 min), the samples were incubated with FITC-anti-human
Fcγ-specific donkey F(ab)2. The secondary antibodies were
purchased from Jackson ImmunoResearch Laboratories.
Cover slips were mounted with VECTASHIELD (Vector
Laboratories Inc., Burlingame, CA). To assess the extent of
the colocalization of fluorescence signals, the cells were
scanned in a series of 0.5-μms e q u e n t i a ls e c t i o n sw i t ha n
ApoTome System (Zeiss, Oberkochen, Germany) connected
with an Axiovert 200 inverted microscope (Zeiss); image
analysis and 3D reconstruction were then performed by the
Axiovision software (Zeiss). A quantitative analysis of the
extent of colocalization was performed using the Zeiss
KS300 3.0 Image Processing system (Zeiss). The mean±
standard error (SE) percent of colocalization was calculated
analyzing a minimum of 30 cells for each treatment
randomly taken from three independent experiments.
E75-specific CD8
+ T cell enrichment




+ T cells were purified using CD8
MicroBeads (Miltenyi Biotech). CD8
− cells were pulsed with
the E75 HER2 HLAI-A2 restricted epitope (KIFGSLAFL)
(ClinAlfa, Germany) (50 μg/ml) and β2-microglobulin
(Sigma) (5 μg/ml). After overnight incubation, irradiated
E75-pulsed CD8
− cells were added to CD8
+ Tc e l l s( 1 : 1 ) .
Interleukin (IL)-2 (50 U/ml) and IL-7 (10 ng/ml) were added
to the culture. A second stimulation was performed after
9 days. E75-specific CD3
+/CD8
+ T cells were analyzed by
J Mol Med (2011) 89:1231–1240 1233staining with PE-HLA-A*0201 Pro5-pentamer containing
the E75 epitope (ProImmune, Oxford, UK).
IFN-γ ELIspot
iDCs were pulsed with HER2-Fc and Ctrl-Fc proteins (10 μg/
ml) and E75peptide (20 μg/ml) withβ2-microglobulin(5μg/
ml) (Sigma) for 4–8 h and matured. Pulsed mDCs (2×10
4
cells per milliliter) were plated with autologous E75-
stimulated CD8
+ T cells (1×10
5 cells per milliliter) onto
plates (Millipore, Bedford, MA), precoated with the anti-
IFN-γ MoAb (NIB42, Pharmingen, San Diego, CA) for
24 h. Cells were removed and IFN-γ production was
detected with biotinylated anti-IFN-γ MoAb (4S.B3,
Pharmingen) (5 μg/ml), revealed with streptavidin–alkaline
phosphatase (Pharmingen) (1:2,000), and BCIP/NBTalkaline
phosphatase substrate (50 μl/well, Sigma). Unpulsed mDCs
plated with CD8
+ cells were used as negative control (IFN-γ
spots <6/10
5 cells). Spots were counted using the Immuno-
Spot Image Analyzer (Aelvis, Germany). Results were
plotted as median of spot values among triplicates.
Statistical analysis
Descriptive statistics (average and standard deviation) were
usedtodescribevariousgroupsofdata.Atwo-tailedStudent’s
t test was adopted to compare the different groups of data. A
statistical significance was set at a p value less than 0.05.
Results
Generation of the recombinant HER2-Fc and Ctrl-Fc chimera
The human IgG1 Fc fragment was used as cell-binding
domain to deliver HER2 tumor antigen to DCs. The HER2-
Fc cDNA was made by cloning the leader sequence of a
murine κ chain (LS) in front of the HER2(364–391) coding
sequence containing the immunogenic epitope E75 (KIFG-
SLAFL) (Fig. 1a). The HER2 sequence was mutated
(I370→V370;L 377→V377) to generate a modified E75
epitope with higher binding affinity for HLAI-A2 allele
(KVFGSLAFV). This fragment was then linked in frame to
the amplified human Fc IgG1 cDNA. The Ctrl-Fc construct
was made by linking the LS and Fc sequences (Fig. 1a).
Stable CHO-K1 transfectants efficiently secreted the pro-
teins. HER2-Fc, and Ctrl-Fc displayed the expected
molecular weight (59.4 and 53.4 kDa, respectively) as
detected by Western blotting (Fig. 1b). In reducing
conditions, HER2-Fc and Ctrl-Fc migrated as bands
corresponding to 29.7 and 26.7 kDa, respectively, indicat-
ing that both recombinant proteins were secreted as dimers
(Fig. 1b).
HER2-Fc vaccination induces longer survival in BALB/c
mice transplanted with HER2
+ mammary tumor
Immunogenicity of HER2-Fc cDNA was evaluated in vivo
in tumor rejection mouse model. BALB/c mice were
vaccinated twice at 2-week intervals and 1 week after the
second vaccination challenged s.c. with mouse mammary
D2F2/E2 tumor cells, transfected with the human HER2
antigen. A growing tumor was displayed by all mice
vaccinated with the empty pcDNA3.1 plasmid, whereas
about 50% protection was afforded by both Ctrl-Fc and
HER2-Fc plasmids (Fig. 2a). A delay in tumor growth was
observed in three out of five mice vaccinated with HER2-
Fc as compared to those vaccinated with Ctrl-Fc or with
pcDNA3.1 (Fig. 2b). Moreover, the tumor latency in mice
vaccinated with HER2-Fc was higher as compared to those
vaccinated with Ctrl-Fc (44.3±3.9 days vs 26.8±2.7 days).
Indeed, the mean time required for a carcinoma to exceed a
10-mm threshold was 91±10.4 days in mice vaccinated
with HER2-Fc, and it was significantly longer (p=0.02) as
compared to the one measured in mice vaccinated with
Ctrl-Fc (58±3.9 days).
HER2-Fc vaccination promotes CD8
+ T cell-mediated
IFN-γ secretion in BALB/c-vaccinated mice
To test if the delay in tumor growth observed in HER2-Fc-
vaccinated mice was due to the ability of the vaccine to
induce HER2-specific T cell responses, we evaluated in
vitro IFN-γ secretion of splenocytes from vaccinated mice
by ELIspot assay. The HER2(364–391) sequence coded by
HER2-Fc chimera (FAGCKKVFGSLAFVPESFDGD
PASNTAP) and the corresponding native HER2 sequence
(FAGCKKIFGSLAFLPESFDGDPASNTAP) were scanned
for H2
d class I binding peptides using the prediction
algorithm used by the software “SYFPEITHI” [17], in
order to select human HER2 immunogenic epitopes
presented by mouse APCs in the context of H2
d. Five
nonapeptides with high score for H2
d binding (>13) were
selected: three nonapeptides derived from the modified
HER2 peptide sequence of the vaccine (GCKKVFGSL,
KVFGSLAFV and KKVFGSLAF) and two nonapeptides
contained in the wt HER2 sequence (GCKKIFGSL and
KIFGSLAFL) (Table 1). SPCs of the cDNA-vaccinated mice
were incubated overnight with each of the epitopes derived
from the HER2-modified sequence encoded by the vaccine,
and T cell-mediated response was measured by IFN-γ
ELIspot assay. Following HER2 peptide stimulation, SPCs
from HER2-Fc-vaccinated mice displayed a significantly
higher number of IFN-γ producing T cells as compared to
those elicited by Ctrl-Fc vaccination (Fig. 3a, c, e; p=0.0004
for A and E, p=0,008 for C). Also, a significant HER2-
specific T cell-mediated IFN-γ response was elicited by
1234 J Mol Med (2011) 89:1231–1240stimulation with the corresponding native HER2 epitopes
(Fig. 3b, d; p=0.008 and p=0.0004, respectively). These
results suggested that cDNA vaccination induced specific
HER2 T cell responses reacting with the modified HER2
sequences and could cross-react with the native HER2
peptides.
HER2-Fc chimera protein internalized through FcγR
is cross-processed by DCs
In order to evaluate whether HER2-Fc protein could be a
valid immunogen to load DCs, uptake and processing of
HER2-Fc were investigated employing DCs differentiated
from human PBMCs. DCs generated in serum-free medium
for ex vivo use, expressed preferentially the activatory
FcγRIIa (Supplementary Data, Fig. 1). HER2-Fc binding to
DC surface was completely inhibited by the treatment with
a blocking antibody towards this FcγR (Supplementary
Data, Fig. 2). After binding at 4°C, HER2-Fc intracellular
processing was characterized 2 and 12 h after uptake by
fluorescence microscopy (Fig. 4). The HER2-Fc protein
was visualized with FITC-conjugated F(ab)2 anti-human
IgGγ Fc-specific Ab (green), while compartment markers
were labeled in red.
The HLAI molecule was employed to identify HLA
class I compartment (ER
+ and HLAI
+ vesicles), while
calreticulin was used to specifically define ER
+ compart-
ment. LAMP1 distribution marked endolysosomal/HLAII
compartment.
Two hours after internalization, HER2-Fc was localized
in discrete granules in the 85–90% of the analyzed cells and
appeared mostly to be associated to HLAI compartment. In
fact, absolute percentage values of colocalization indicated
that the processed protein predominantly colocalized with
Fig. 2 HER2-Fc cDNAvaccination and antitumor response elicited in
BALB/c mice. Groups of mice were vaccinated twice at 2 weeks
interval with empty pcDNA3.1 (n=5; gray line), Ctrl-Fc (n=10;
dotted black line), and HER2-Fc (n=11; black line) and challenged
1 week after the second vaccination with a lethal dose of D2F2/E2
cells transfected with the human HER2. a The percentage of tumor-
free mice in function of time is represented. b Ability of vaccination to
delay tumor growth. Each line refers to an individual tumor
(pcDNA3.1, n=5; Ctrl-Fc, n=5; HER2-Fc, n=5)
Fig. 1 Generation and characterization of HER2-Fc and Ctrl-Fc proteins.
a Diagrams illustrating the cDNA structures of the two chimeric cDNAs.
The coded amino acid sequence of the HER2 region used is shown
(modified amino acids are underlined) (LS, leader sequence; HER2
indicates the amino acid stretch 364–391). b Western blot analysis of
HER2-Fc and Ctrl-Fc. Proteins (1 μg/sample) were fractionated in
nonreducing and reducing conditions (±β-mercaptoethanol) in SDS-
PAGE 4–12% gradient gel and blotted onto nitrocellulose. Western
blotting was performed using peroxidase-conjugated MoAb anti-Fcγ
revealed by chemiluminescence
J Mol Med (2011) 89:1231–1240 1235HLAI in the perinuclear area (57%) (orange/yellow signal)
(Fig. 4, first and second columns) and partially overlapped
with calreticulin (29%). HER2-Fc staining was also
associated, but to a less extent, to LAMP1
+ granules (17%).
After 12 h, HER2-Fc cytoplasmic staining was more
diffuse, maintaining the colocalization pattern with a slight
increase in HLAI compartment (absolute values: HLAI
63%, calreticulin 20%, LAMP1 7%) (Fig. 4, third and
fourth columns). These results indicated that HER2-Fc was
processed in both HLAI and HLAII compartments and that
already after 2 h it could be found predominantly associated
to HLAI
+ areas.
HER2-Fc-pulsed DCs induce CD8
+ T cell-mediated IFN-γ
secretion in breast cancer patients
We further studied HER2-Fc ability to stimulate HER2-
specific CD8
+ T cells in HER2
+/HLAI-A2
+ breast cancer
patients. In vitro-enriched E75-specific CD8
+ T cells, were
plated with autologous DCs pulsed with HER2-Fc or Ctrl-
Fc proteins (DCHER2-Fc or DCCtrl-Fc, respectively), and T
cell-mediated response was measured by IFN-γ ELIspot
assay (Fig. 5). Each of the CD8
+ T cell cultures secreted
IFN-γ in response to the DCHER2-Fc (black bars) in a
significantly higher amount than DCCtrl-Fc (light gray bars)
(p<0.05). In three patients, stimulation of CD8
+ T cells by
E75-pulsed DCs (10 μg/mL; DCE75-dark gray histograms)
resulted in an IFN-γ response lower than DCHER2-Fc and
above DCCtrl-Fc.
Discussion
DC-based immunotherapy is an attractive therapeutic
approach to be combined with standard therapies for the
induction of long lasting antitumor immunity, aiming at the
control of cancer progression. The clinical effectiveness of
such an approach is documented by an increasing number
of clinical trials and has been confirmed by the recent FDA
approval of the first DC-based autologous vaccine [18]. A
critical key step in the DC vaccine design is the modality of
antigen delivery to DCs in vivo as well ex vivo [6]. Several
experimental evidences indicate that antigen DC targeting
through FcγR is an optimal strategy for anticancer
immunotherapy [3]. However, so far, such clinical approach
is limited to idiotype-pulsed DC vaccines, employed with
controversial results in the therapy of hematological
malignancies [11]. In mouse models, vaccination with
cDNA coding viral/tumor-associated antigen fused with
human Fc has been shown to exert prophylactic and
therapeutic efficacy, although with a broad heterogeneity
in the vaccination schedules and in the choice of therapeutic
endpoints [9, 19, 20].
Fig. 3 CD8
+ T cell-mediated IFN-γ response in BALB/c vaccinated
mice. ELIspot analysis of IFN-γ-producing cells after restimulation of
spleen cells with H-2
d peptides derived from the HER2 modified
sequence encoded by the vaccine (a, c, e) or from the native HER2
sequence (b, d). IFN-γ secretion by SPCs from mice (n=3) vaccinated
twice with the Ctrl-Fc (gray) or with the HER2-Fc (black) was
expressed as spot-forming unit and mean of triplicate plotted as
histograms. Data were analyzed using the two-tailed Student’s t test
(**p=0.008; ***p=0.0004)
















aThe mutated amino acid residues are indicated in bold and
underlined.
bMeasure of the probability of each peptide to bind H2
d molecules
generated from SYFPEITHI algorithm http://www.syfpeithi.de/
Scripts/MHCServer.dll/EpitopePrediction.htm
1236 J Mol Med (2011) 89:1231–1240Objective of thiswork was to generate a HER2-Fc chimera
toloadDCsinvivoandexvivoasantitumorvaccine.Weused
the HER2 antigen because it is a clinically relevant target for
both passive and active immunotherapies. The administration
Fig. 4 Intracellular localization of HER2-Fc in iDCs after FcγR-
mediated internalization. Immunofluorescence analysis of HER2-Fc
intracellular localization in DCs after 2 or 12 h from the uptake. The
HER2-Fc protein is visualized in green, while the HLAI compartment
(identified by calreticulin and HLAI staining) or the endolysosomal
HLAII compartment (LAMP1 staining) are immunolabeled in red.3 D
reconstruction of a selection of three central sections crossing the
nucleus out of the total number of the serial optical sections is shown
in each image. A quantitative analysis of the percentage of
colocalization was performed by serial optical sectioning and 3D
reconstruction. Results are expressed as mean values±SE (standard
errors); the percentage of colocalization was calculated analyzing a
minimum of 30 cells for each treatment randomly taken from three
independent experiments. After 2 h of internalization, the HER2-Fc
staining appears in dots clustered in the perinuclear area of the cells.
HER2-positive spots colocalize with the HLAI compartment (57%
colocalization with HLAI and 29% colocalization with calreticulin)
and only partially with the HLAII compartment (17% colocalization
with LAMP1). Arrows point to yellow double-positive spots. After
12 h of internalization, HER2-positive dots are more scattered
throughout the entire cytoplasm and the colocalization with HLAI
compartment appears only slightly increased. Bar,1 0μm
J Mol Med (2011) 89:1231–1240 1237of humanized HER2-specific antibody Trastuzumab is now-
adays a consolidation treatment for the management of breast
cancer as well as other epithelial cancers [21, 22]. Moreover,
HER2 peptide vaccinations have been shown to induce
HER2-specific immune responses and to be associated with
a better survival of the vaccinated patients [13, 23]. We
selected the HER2(364–391) region, spanning the E75 HLA-
A2-restricted epitope, modifying the anchor residues to
increase binding affinity [24] and fusing this sequence to
the Fc fragment of human IgG1. The immunogenicity of the
HER2-Fc chimera was tested both as a cDNA vaccine in a
mouse model and as a protein in an in vitro human setting
utilizing DCs that represent the optimal target for this
immunogen.
In mice, two HER2-Fc cDNA vaccinations were suffi-
cient to activate an anti-HER2 specific immune response
and to increase tumor latency with a significantly longer
survival than the Ctrl-Fc cDNA. SPCs from HER2-Fc-
vaccinated mice produced significant levels of IFN-γ in
response to human HER2 epitopes, selected as strong
binders to H2
d MHC class I molecules. Almost no IFN-γ
secretion was detected in Ctrl-Fc-vaccinated mice. These
results indicated that HER2-Fc cDNA was correctly
translated, the antigenic sequence processed and efficiently
presented in vivo.
It is interesting to note that the vaccination with the
modified HER2 sequences induced significative response
against the epitopes contained in the vaccine as well as the
corresponding native HER2 sequences [24]. A third cDNA
vaccination did not significantly modify such a response
(data not shown). Recent experimental evidences have
highlighted the key role of antigen-specific immunosurveil-
lance in limiting tumor outgrowth by cytolytic and
cytostatic T cell-mediated mechanisms [25]. We assume
that the delayed tumor growth and the longer survival
observed in mice vaccinated with HER2-Fc cDNA could be
due to the anti-HER2 T cell responses specifically elicited
by the cDNA vaccine. Both HER2-Fc and Ctrl-Fc vaccina-
tion induced 50% tumor protection (at day 100 from
challenge), while empty vector-vaccinated mice displayed
100% tumor growth, suggesting that the Fc sequence could
exert an unspecific antitumor effects at early stage of tumor
engraftment. It is well-known that innate immunity plays a
fundamental role during cancer immunosurveillance at
early stages, when innate immune mechanisms are involved
in the recognition and killing of transformed cells thus
Fig. 5 CD8
+ T cell-mediated IFN-γ response to HER2-Fc in HLAI-
A2
+/HER2
+ breast cancer. ELIspot analysis of IFN-γ production by
CD8
+ T cells plated with antigen-pulsed autologous DCs (50:1). IFN-
γ secretion was evaluated as number of spots and mean of triplicate
plotted as histograms (black, HER2-Fc-pulsed DCs; light gray, Ctrl-
Fc-pulsed DCs; dark gray, E75-pulsed DCs). Data were analyzed
using the two-tailed Student’s t test (*p<0.05; **p≤0.005)
1238 J Mol Med (2011) 89:1231–1240preventing the development of malignancy [26]. The Fc
portion of the chimera vaccine, could most probably
interact with FcγR expressed in vivo by DCs and by other
innate immune cells thus exerting an aspecific antitumor
effects. In this context, the Fc domain in the cDNA vaccine
could be regarded as an adjuvant component, contributing
to the activation of the innate immune network. We are
currently investigating this hypothesis in FcγR KO mice.
The immunogenicity of the HER2-Fc molecule was also
evaluated as a protein in human experimental settings. The
HER2-Fc chimera, secreted as a dimer, could homoge-
nously target DCs grown in clinical grade conditions
through the FcγRIIa, the activatory receptor preferentially
expressed by DCs differentiated in serum-free media
(Supplementary Data). The bound HER2-Fc protein was
readily internalized and colocalized within 2 h in HLAII and,
most predominantly, in HLAI and calreticulin compartments
as shown by immunofluorescence studies, suggesting that the
vast majority of the protein could be cross-processed.
Intracellular processing of soluble tumor antigens is
often blocked in HLAII compartment, likely inducing an
exclusive CD4
+ T cell-mediated response [27, 28]. The
delivery of soluble antigens through FcR could redirect
antigen processing also into HLAI pathway. To our
knowledge, this is the first demonstration that a monovalent
chimeric ligand for FcγR is efficiently processed as
polyvalent immunocomplexes are [3].
The ability of DCs pulsed with HER2-Fc to induce a
specific anti-HER2 immune response was tested in autolo-
goussettinginvitro,usingE75-specificCD8
+ Tcells from six
HER2
+/HLA-A2
+ patients. For each patient, the enriched
E75 CD8
+ T cells secreted a significant higher amount of
IFN-γ in response to HER2-Fc loaded DCs (p<0.05) as
compared to DCs pulsed with the Ctrl-Fc protein as
evaluated in ELIspot assay. The consistent IFN-γ response
to DCCtrl-Fc observed in some patients may be due to
allotypic residues present in the Fc domain. When the HER2
epitope was targeted to DCs through FcγR, the amount of
antigen required to induce a specific IFN-γ response was 80
fold less as compared to the E75 peptides (0.025 μmol
HER2-protein vs 2 μmol E75 peptide). These results
confirmed that HER2-Fc was efficiently processed and
HER2 presentation occurred resulting in the activation of
specific IFN-γ CD8
+ T cell-mediated responses.
It is now clear that the standard treatments such as
surgery, radio, and chemotherapy can have a strong
interplay with the immune system [29, 30], and that
immune activation contributes significantly to the efficacy
of classical cancer treatments. Following this line of
evidence, the use of distinct immunotherapeutic interven-
tions to induce, reinforce, and maintain a long lasting
immune response is strongly encouraged. Targeting DCs
through FcγRs can foresee the combined use of the same
antigen in two distinct immunogen formulations both as
protein and as cDNA.
In conclusion, we have produced a recombinant HER2-
Fc chimera for targeting DCs in vivo and in vitro. cDNA
vaccination activated anti-HER2 epitope-specific CD8
+ T
cells and afforded a longer survival in mice immunized
with HER2-Fc plasmid. In vitro, DCs pulsed with HER2-Fc
protein induced a significant IFN-γ secretion by HER2-
specific CD8
+ T cells, as detected in breast cancer patients.
This immunogen has several advantages as compared to
protein/peptide-based formulation. The antigen domain can
be engineered to contain multivalent sequences of the same
or different antigens, providing a multi-epitope vaccination.
This would overcome the requirement of knowledge of
patients’ haplotype and supplying epitopes for a concom-
itant HLAI and HLAII presentation as long peptides do
[31]. Engineering of the Fc domain could tune the FcγR
binding affinity with huge impact on the enhancement of
antigen cross-processing and on DCs activation [3, 32].
Moreover this antigenic formulation offers the option to be
efficaciously employed as cDNA and as protein formula-
tion in prime boost strategy in patient tailored, integrated
therapies.
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